New MRI method could revolutionize prostate cancer screening for High-Risk men

NCT ID NCT05384535

Recruiting now Diagnosis Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a simpler type of MRI, called biparametric MRI (bpMRI), can improve prostate cancer screening in men at high risk, such as Black men or those with a family history of the disease. The researchers will combine bpMRI with standard PSA blood tests to see if they can detect suspicious lesions earlier and more accurately. The goal is to make screening safer by avoiding contrast dye and reducing unnecessary biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bi-parametric MRI (bpMRI)
What this could lead to: If successful, this could make prostate cancer screening more accurate and safer for high-risk men, reducing unnecessary biopsies.
What could go wrong: This is a small, early-phase study with only 100 participants, so results may not apply to everyone. The MRI might miss some cancers or find false positives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAGNETIC RESONANCE IMAGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAGNETIC RESONANCE IMAGING POPULATION AT RISK PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Cynthia Knauer
RECRUITING

Lake Success, New York, 11042, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.